/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.
This is the third part in our year-end Public Markets Special for 2023. Read more about it here.
Laurus Labs isn’t likely to be top of mind if you’re asked to name a bunch of Indian companies in the pharmaceuticals business. It's probably not high on recall even in its base, Hyderabad, headquarters to several drug manufacturers, including the likes of Dr Reddy’s Laboratories, Aurobindo Pharma and Natco Pharma.
Yet, as of Tuesday, Laurus Labs’s shares are among the most expensive in the industry if you go by the popular valuation metric—the price-to-earnings, or P/E, ratio. At a P/E …
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
